Merck (NYSE:MRK) is preparing to launch a subcutaneously delivered formulation of their blockbuster cancer medication Keytruda for patient convenience as the company approaches a steep patent ...

and Keytruda (pembrolizumab) resulted in promising clinical activity, study results have shown. Results from a small retrospective analysis were shared in a poster at the 2025 ASCO Genitourinary ...